Egen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2002-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.egeninc.com
A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2015-07-13
- Lead Sponsor
- EGEN, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT01300858
- Locations
- 🇺🇸
Midwestern Regional Medical Center, Zion, Illinois, United States
Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer
Phase 1
Completed
- Conditions
- Ovarian Neoplasms
- Interventions
- Genetic: EGEN-001 (phIL-12-005/PPC)
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- EGEN, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT00473954
- Locations
- 🇺🇸
Oncology Specialties, PC, Huntsville, Alabama, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer
Phase 1
Terminated
- Conditions
- Ovarian Neoplasms
- Interventions
- Genetic: EGEN-001 (phIL-12-005/PPC)
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- EGEN, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT00137865
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
© Copyright 2025. All Rights Reserved by MedPath